Comparison
Liraglutide vs. Sermorelin
Two peptides side-by-side — identity, evidence base, legal status and known adverse events.
Identity
Category
Metabolic
Growth
CAS no.
204656-20-2
86168-78-7
Molecular weight
3751 g/mol
3358 g/mol
Half-life
13 h
0.2 h
Sequence
HAEGTFTSDVSSYLEGQAAKEFIAWLVRGRGYADAIFTNSYRKVLGQLSARKLLQDIMSRMechanism of action
Liraglutide
Liraglutide is a synthetic GLP-1 analog with 97% sequence identity to human GLP-1. A fatty-acid side chain (C16) on Lys-26 reversibly binds serum albumin and protects against DPP-4 degradation. GLP-1 receptor activation glucose-dependently stimulates insulin secretion, inhibits glucagon secretion, delays gastric emptying and modulates central satiety.
Sermorelin
Synthetic analogue of the first 29 amino acids of human growth-hormone-releasing hormone (GHRH). Stimulates pulsatile endogenous growth-hormone secretion from the pituitary via the GHRH receptor. Very short plasma half-life — pharmacodynamic effect lasts several hours nevertheless.
Evidence base
Highest evidence
Human RCT
Human RCT
Studies
5
5
of which in humans
4
3
Effects recorded
3
3
Open conflicts
0
1
Documented adverse events
1
3